6th patient conversion in InVivo’s INSPIRE Study— 5 observations

Cambridge, Mass.-based InVivo Therapeutics reported the sixth patient conversion in its INSPIRE study testing the Neuro-Spinal Scaffold.

Advertisement

Here are five observations:

 

1. The patient has improved, going from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury, between discharge and the one-month follow-up.

 

2. The study has now seen a 54.5 percent conversion rate among the 11 enrolled patients.

 

3. The patient enrolled in the INSPIRE study at Charlotte, N.C.-based Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation in December 2016.

 

4. Domagoj Coric, MD, and Samuel Chewning, MD, implanted the Neuro-Spinal Scaffold in the patient.

 

5. The INSPIRE study tests the Neuro-Spinal Scaffold’s efficacy and safety for complete thoracic AIS A spinal cord injury.

 

More articles on devices:
Hip, knee orthopedic surgical implants to surge to $33B by 2022; Zimmer Biomet dominating market — 5 things to know
Bioventus appoints John Nosenzo new chief commercial officer: 7 thoughts
Xtant Medical CEO Dan Goldberger resigns: 5 key points

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.